Sensus Healthcare (NASDAQ:SRTS) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Sensus Healthcare (NASDAQ:SRTS) from a sell rating to a hold rating in a research report report published on Saturday morning.

SRTS has been the subject of several other research reports. Weiss Ratings reissued a “sell (d)” rating on shares of Sensus Healthcare in a research note on Wednesday, October 8th. HC Wainwright cut their price target on Sensus Healthcare from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Tuesday, August 12th. Zacks Research upgraded shares of Sensus Healthcare from a “strong sell” rating to a “hold” rating in a report on Wednesday, October 22nd. Finally, Lake Street Capital reduced their price objective on shares of Sensus Healthcare from $13.00 to $6.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.00.

Sensus Healthcare Price Performance

Shares of Sensus Healthcare stock traded up $0.68 during trading hours on Friday, hitting $4.20. The company’s stock had a trading volume of 264,443 shares, compared to its average volume of 168,941. Sensus Healthcare has a 12 month low of $3.03 and a 12 month high of $9.33. The company has a market capitalization of $69.05 million, a PE ratio of -70.00 and a beta of 1.38. The stock has a 50 day moving average of $3.28 and a 200 day moving average of $4.08.

Sensus Healthcare (NASDAQ:SRTS) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.06. The firm had revenue of $6.88 million for the quarter, compared to analyst estimates of $6.31 million. Sensus Healthcare had a negative net margin of 2.26% and a negative return on equity of 1.58%. Equities analysts expect that Sensus Healthcare will post 0.32 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Larson Financial Group LLC bought a new stake in Sensus Healthcare in the 1st quarter worth about $26,000. Vise Technologies Inc. purchased a new position in shares of Sensus Healthcare in the 2nd quarter worth approximately $52,000. IFP Advisors Inc boosted its stake in shares of Sensus Healthcare by 37.2% in the 1st quarter. IFP Advisors Inc now owns 18,800 shares of the company’s stock worth $89,000 after buying an additional 5,100 shares during the last quarter. Trexquant Investment LP bought a new position in shares of Sensus Healthcare in the first quarter valued at approximately $93,000. Finally, American Century Companies Inc. boosted its position in Sensus Healthcare by 12.7% in the first quarter. American Century Companies Inc. now owns 22,440 shares of the company’s stock worth $106,000 after purchasing an additional 2,520 shares during the last quarter. Hedge funds and other institutional investors own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.